SS2. Outcomes of Interventions for Recurrent Disease after Endoluminal Intervention for Superficial Femoral Artery Disease  by Younnes, Houssan K. et al.
2009 Vascular Annual Meeting—Plenary SessionsS1: William J. von Liebig Forum
SS1.
Lower Extremity Angioplasty: Impact of Practitioner Specialty and
Volume on Indications and Resource Utilization
Todd R Vogel, Viktor Y Dombrovskiy, Paul B Haser, Jeffrey L Carson, Alan
M Graham. UMDNJ-Robert Wood Johnson Medical School, New Bruns-
wick, NJ
Objectives: Lower extremity percutaneous transluminal angioplasty
(LE PTA) is currently performed by a variety of endovascular specialists. We
hypothesized that cardiologists (CRD) and vascular surgeons (VAS) may
have different practice patterns, thresholds for intervention, and hospital
utilization.
Methods: Analysis of the State Inpatient Databases for New Jersey
(2003-2007). Patients with elective admission undergoing PTA procedures
with indications of claudication, rest pain, and ulceration/gangrene were
examined. Physician specialty was determined based on all procedures
performed. LE PTAwas analyzed with respect to specialty, indication for the
procedure, volume, and resource utilization.
Results: 1887 cases of LE PTA were identified [VAS 866 (45.9%) and
CRD 1021 (54.1%)]. Mean age was 69.7 (CRD) vs. 71.7(VAS), p0.0049.
Indications for intervention were compared for CRD vs. VAS: claudication
80.7% vs. 60.7%, (p0.002); rest pain 6.2% vs. 16.0%, (p0.002); gan-
grene/ulceration 13.1% vs. 23.3%, (p0.002). Stents (64.8% of cases) were
utilized similarly among physicians (p.18) and practitioners had similar
lengths of stay (2.38 days vs. 2.41 days, p0.85). Hospital charges by
indication varied between CRD vs. VAS: All procedures: $56,687 vs.
$44,077 (p0.001); claudication: $46,669 vs. $ 38,100 (p.0001); rest
pain $59,034 vs. $39,755 (p0.0009); gangrene/ulceration $64,357 vs.
$54,375 (p0.018). Revenue center charges were different between CRD
vs. VAS: Medical surgical supply $18,906 vs. $12,920, (p0.001); Phar-
macy $3,197 vs. $1,281, (p0.001). Only 10.7% of CRDwere high volume
practitioners compared to 36.8% of VAS (p0.05). High volume practitio-
ners had significantly lower hospital charges ($42,168 vs. $ 50,967,
p0.001).
Conclusions: Cardiologists performing lower extremity angioplasty
were more likely to treat patients with claudication than rest pain or
gangrene. Despite treating younger patients with less severe peripheral
vascular disease, cardiologists used significantly greater hospital resources.
High practitioner volume, regardless of specialty, was associated with lower
hospital resource utilization. Tempering lower extremity intervention based
on indication and practitioner volume may permit future cost savings.
Author Disclosures: T.R. Vogel, AmericanHeart Association;V.Y. Dom-
brovskiy, None; P.B. Haser, None; J.L. Carson, National Heart, Lung,
and Blood Institute; A.M. Graham, None.
SS2.
Outcomes of Interventions for Recurrent Disease after Endoluminal
Intervention for Superficial Femoral Artery Disease
Houssan K Younnes, Jean Bismuth, Joseph J Naoum, Imran T Mouhiddin,
Eric K Peden, Alan B Lumsden, Mark G Davies. Methodist DeBakey Heart
and Vascular Center, Houston, TX
Objective: Aggressive endoluminal therapy for superficial femoral ar-
tery (SFA) occlusive disease is commonplace, but the outcomes of current
management of recurrent disease has not been well defined. The purpose of
this study is to examine the outcomes of endoluminal and open interventions
for recurrent SFA disease.
Methods: A database of patients undergoing endovascular treatment
of the SFA between 1986 and 2008 was retrospectively queried. Patients
who developed recurrent disease were selected. Kaplan-Meier survival anal-
yses were performed to assess time-dependent outcomes. Factor analyses
were performed using a Cox proportional hazard model for time dependent
variables. Data are presented as meanSEM.
Results: 735 limbs in 631 patients (64%% male, average age 67 years)
underwent endovascular treatment for symptomatic SFA disease. The reste-
nosis rate was 163% at 5 years. Of the 222 patients, 58 remained asymp-
tomatic while 164 underwent repeat intervention (59% percutaneous and
41% bypass). Bypass was employed for more extensive recurrent disease
(Table). While primary and Repeat PTA had equivalent patency and symp-tom relief, those undergoing bypass had significantly superior outcomes
albeit with a higher morbidity (Table). TASC lesion and runoff were
significant predictors of failure in the repeat PTA group.
Primary
PTA
Repeat
PTA Bypass
Number Limbs at Risk (n) 735 96 68
Claudication (%) 51 71 36
†
Rest Pain / Tissue Loss (%) 49 29 64
†
TASC C and D lesions (%) 38 42 67*
Mortality (%) 1 2 0
†
Morbidity (%) 16 16 28*
†
Freedom from Recurrent
Symptoms (%)
663 636 818*
†
Primary Patency (%) 603 634 685
Assisted Primary Patency (%) 713 743 847*
†
Secondary Patency (%) 739 733 938*
†
MeanSEM at five years follow up.
*p0.05 compared to Primary PTA.
†p0.05 compared to Repeat PTA.
Conclusions: Repeat percutaneous intervention for recurrent SFA
disease is associated with similar outcomes to the primary intervention.
However, bypass for recurrent disease is used more commonly for extensive
disease and is associated with superior longterm outcomes. This study
suggests that bypass rather than repeat PTA may be the better strategy for
recurrent disease.
Author Disclosures: H.K. Younnes, None; J. Bismuth, None; J.J.
Naoum, None; I.T. Mouhiddin, None; E.K. Peden, None; A.B. Lums-
den, None; M.G. Davies, NIH; BSC.
SS3.
Validation of the PIII CLI Risk Score for the Prediction of Amputa-
tion-Free Survival (AFS) in Patients with Critical Limb Ischemia
Andres Schanzer1, Philip P Goodney2, Youfu Li1,Mohammad Eslami1, Jack
Cronenwett2, Louis Messina1, Michael S Conte3, The Vascular Study
Group of Northern New England. 1University of Massachusetts Medical
School, Worcester, MA; 2Dartmouth-Hitchcock Medical Center, Lebanon,
NH; 3University of California San Francisco, San Francisco, CA
Objective: The PIII CLI risk score (previously published) is a simple
tool for estimating AFS in CLI patients considered for infrainguinal bypass
(IB). The current study sought to validate this risk stratification model using
the prospective Vascular Study Group of Northern New England (VS-
GNNE) database.
Method:Wecalculated the PIIICLI risk score for 1579 patients receiving
IB by 59 surgeons at 11 hospitals. Each patient’s score (dialysis 4 pts, tissue loss
3 pts, age75 2 pts, CAD 1 pt) was calculated to stratify patients into low (3
pts), med (4-7 pts), and high (8 pts) risk categories. Baseline hematocrit was
not included due to a large proportion ofmissing values. Kaplan-Meier method
was used to calculate AFS for the 3 risk groups. Log rank test was used for
intergroup comparisons. To assess validation, comparison to the PIII derivation
and validation sets was performed.
Result: Stratification of the VSGNNE patients by risk category yielded
three significantly different estimates for 1-year AFS (84.7%, 73.5%, and
54.5%, for low, med, and high risk groups, Fig). Intergroup comparison
demonstrated precise discrimination (p.0001). For a given risk category
(low, med, high), the 1-year AFS estimates were consistent between the
VSGNNE dataset and the PIII derivation set (85.9%, 73.0%, 44.6%), PIII
validation set (87.7%, 63.7%, 45.0%), and the retrospective validation set
(86.3%, 70.1%, 47.8%) (Fig).
Conclusion: The PIII CLI risk score has now been tested in 3699 CLI
patients at 94 institutions by a diverse array of physicians. This tool provides
a simple and reliable method to risk stratify CLI patients being considered
for IB. At initial consultation, patients with a 50% chance of death or major
amputation at 1 year can be identified.
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